Dealing With MedImmune
Many observers believe that this decision will fundamentally alter the negotiating positions of prospective licensors and licensees. Until MedImmune, a licensee could not make a validity challenge without first repudiating the license, refusing to pay royalties and infringing the patent.
The licensee would then face major risks...
To view the full article, register now.